Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Mandatory Trial Reporting To Be Required For Nearly Half Of IND Protocols

Executive Summary

Almost half of investigational new drug trial protocols submitted to FDA will be subject to mandatory reporting requirements for trials of drugs for serious or life-threatening diseases, the agency estimated in a March 29 notice of draft guidance availability

You may also be interested in...

Experimental Cancer Drug Access To Be Topic Of FDA Consensus Conference

FDA is planning a consensus conference to discuss issues surrounding single-patient INDs and expanded access programs for unapproved oncology agents, Oncologic Drug Products Division Medical Team Leader Grant Williams, MD, told FDA's Oncologic Drugs Advisory Committee June 7.

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts